NCT06201442

Brief Summary

The purpose of this trial is to define knee joint pathomechanics (KJPM) in the first 2 years after ACL reconstruction (ACLR) and relate these KJPM with changes in articular cartilage morphology and quality.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 23, 2021

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

January 26, 2023

Completed
12 months until next milestone

First Posted

Study publicly available on registry

January 11, 2024

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2025

Completed
Last Updated

January 11, 2024

Status Verified

August 1, 2023

Enrollment Period

3.4 years

First QC Date

January 26, 2023

Last Update Submit

December 28, 2023

Conditions

Keywords

ACLRAnterior cruciate ligament injuryPTOApost-traumatic knee osteoarthritisKJPMknee joint pathomechanics

Outcome Measures

Primary Outcomes (4)

  • Knee contact forces (KCF) will be measured using a 3D motion analysis system

    The goal is to profile longitudinal changes in KCFs of the articular cartilage. Using a 3D motion analysis system (Vicon, Oxford Metrics, UK), marker trajectories, ground reaction forces (AMTI, MA, USA) and muscle activations (Wireless EMG Cometa, Italy) will be measured. Subsequently a musculoskeletal modelling workflow in OpenSim will be used to calculate Knee contact forces (KCF) of the articular cartilage.

    2 years

  • Knee contact pressures (KCP) will be measured using a 3D motion analysis system

    Using a 3D motion analysis system (Vicon, Oxford Metrics, UK), marker trajectories, ground reaction forces (AMTI, MA, USA) and muscle activations (Wireless EMG Cometa, Italy) will be measured. Subsequently a musculoskeletal modelling workflow in OpenSim will be used to calculate Knee contact pressures (KCP) of the articular cartilage.

    2 years

  • The patient-specific cartilage thickness distribution.

    The cartilage thickness will be measured using the semi-automatic segmentation from the high-resolution images (3D-FSE) of the tibiofemoral cartilage.

    2 years

  • The patient-specific tibiofemoral cartilage quality.

    The cartilage quality will be examined using compositional measures such as T1rho, T1p and T2 relaxation time.

    2 years

Study Arms (2)

Patients undergoing unilateral Anterior Cruciate Ligament Reconstruction (ACLR)

4 - 5 visits: Clinical examination, magnetic resonance imaging (MRI), 3D motion analysis, Strength assessment, EOS radiography (full leg X-ray scan), X-ray scan knee, Blood sample, Questionnaires and Activity monitoring.

Other: Imaging - magnetic resonance imaging (MRI)Other: Blood samplingOther: Assessment of functionality and strengthOther: Activity monitoringOther: Imaging - x-ray scan (RX)Behavioral: Questionnaires

Healthy controls without previous Anterior Cruciate Ligament (ACL) injury

2 visits: Clinical examination, MRI, 3D motion analysis, Strength assessment, EOS radiography, X-ray scan knee, Blood sample, Questionnaires and Activity monitoring.

Other: Imaging - magnetic resonance imaging (MRI)Other: Blood samplingOther: Assessment of functionality and strengthOther: Activity monitoringOther: Imaging - x-ray scan (RX)Behavioral: Questionnaires

Interventions

MRI knee - not standard of care

Healthy controls without previous Anterior Cruciate Ligament (ACL) injuryPatients undergoing unilateral Anterior Cruciate Ligament Reconstruction (ACLR)

blood sample taken and analysis - not standard of care

Healthy controls without previous Anterior Cruciate Ligament (ACL) injuryPatients undergoing unilateral Anterior Cruciate Ligament Reconstruction (ACLR)

Movements and posture Analysis Laboratory Leuven measurement (3D motion analysis) and Biodex measurement - not standard of care

Healthy controls without previous Anterior Cruciate Ligament (ACL) injuryPatients undergoing unilateral Anterior Cruciate Ligament Reconstruction (ACLR)

Actigraph measurement- not standard of care

Healthy controls without previous Anterior Cruciate Ligament (ACL) injuryPatients undergoing unilateral Anterior Cruciate Ligament Reconstruction (ACLR)

RX Knee and EOS radiography full leg - not standard of care

Healthy controls without previous Anterior Cruciate Ligament (ACL) injuryPatients undergoing unilateral Anterior Cruciate Ligament Reconstruction (ACLR)
QuestionnairesBEHAVIORAL

Patient reported outcomes (PROMS)

Healthy controls without previous Anterior Cruciate Ligament (ACL) injuryPatients undergoing unilateral Anterior Cruciate Ligament Reconstruction (ACLR)

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Adult patients up until 35 years old with an ACL reconstruction (recruited at the outpatient clinic) Healthy controls (community sample recruited)

You may qualify if:

  • Age: 18-35 years
  • No previous anterior cruciate ligament (ACL) injury
  • Body Mass Index (BMI) between 18-30
  • Regular physical activity (active during work or practicing sports regularly)
  • Signed informed consent to participate

You may not qualify if:

  • Major injuries to the lower extremities with absence from sports or daily life activities longer than 2 weeks or that required surgery, less than 6 months before participation
  • Pre-existing arthritic disease including inflammatory or infectious arthritis
  • Age: 18-35 years
  • ACL tear which is recently reconstructed or will be reconstructed after enrollment in the current study (the reconstruction will take place within 6 months after injury) with a Hamstring autograft
  • BMI between 18-30
  • Regular physical activity (active during work or practicing sports regularly)
  • Signed informed consent to participate
  • Major injuries to the lower extremities with absence from sports or daily life activities longer than 2 weeks or that required surgery, less than 6 months before participation
  • Pre-existing arthritic disease including inflammatory or infectious arthritis
  • Image based confirmation of local cartilage lesion grade 4 or major cartilage damage (Kellgren \& Lawrence \> 2)
  • Medial collateral ligament damage (\> grade 2)
  • Intra-articular knee fractures
  • Menisectomy with \<80% remnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Kinesiology and Rehabilitation Sciences

Leuven, Vlaams-Brabant, 3001, Belgium

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples

MeSH Terms

Conditions

Anterior Cruciate Ligament Injuries

Interventions

Blood Specimen CollectionSurveys and Questionnaires

Condition Hierarchy (Ancestors)

Knee InjuriesLeg InjuriesWounds and Injuries

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative TechniquesData CollectionEpidemiologic MethodsHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Sabine Verschueren, PhD

    KU Leuven

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 26, 2023

First Posted

January 11, 2024

Study Start

November 23, 2021

Primary Completion

April 1, 2025

Study Completion

April 1, 2025

Last Updated

January 11, 2024

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will share

The full pseudonymized dataset will be made available in RDR (KU Leuven tool) and will be shared upon written request after approval of the PI, for clearly defined research purposes. Pseudonymized data and documentation will be available on request in RDR. Data sharing can only happen when it is not for commercial use or it doesn't reveal the identity of the participants. Data will always be pseudonimized.

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
Upon publication of the research results and for an undetermined period of time.
Access Criteria
Data sharing can only happen when it is not for commercial use or it doesn't reveal the identity of the participants. Data will always be pseudonimized. A written request has to be submitted to the PI.

Locations